Medi Eslani, MD
Glaucoma Specialist · Chula Vista, CANPI 1437614310
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.6% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 28.7% of the total. 2025 is the largest year on record at $2,922, 4.7 times the $618 reported in 2022.
Across 130 payments — averaging $54.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alcon$2K
- Sight Sciences, Inc.$665
- Glaukos Corporation$493
- NEW World Medical,inc.$340
- Mallinckrodt Hospital Products Inc.$310
- plus $1K from 10 others
What the payments were for
- Travel & lodging$4506%
- Food & beverage$6,57194%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $2,015 |
| Alcon | 30 | $1,919 |
| Sight Sciences, Inc. | 9 | $665 |
| Glaukos Corporation | 5 | $493 |
| NEW World Medical,inc. | 5 | $340 |
| Mallinckrodt Hospital Products Inc. | 9 | $310 |
| Apellis Pharmaceuticals, Inc. | 2 | $246 |
| Tarsus Pharmaceuticals, Inc. | 7 | $208 |
| Biotissue Holdings Inc. | 1 | $196 |
| Bausch & Lomb Americas Inc. | 9 | $192 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $139 |
| Nova Eye, Inc. | 1 | $83 |
| Thea Pharma Inc. | 4 | $80 |
| Oyster Point Pharma, Inc. | 2 | $56 |
| Sun Pharmaceutical Industries Inc. | 2 | $44 |
| Dompe US, Inc. | 1 | $35 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI(R) SURGICAL SYSTEM (US)$536
- Clareon$513
- XEN GLAUCOMA TREATMENT SYSTEM$485
- DURYSTA$439
- Hydrus Microstent$372
- Syfovre$246
- iDoseTR$200
- Kahook Dual Blade$153
- Clearpath$153
- Ahmed Glaucoma Valve$153
- Streamline$153
- Via360$153
- ARGOS$148
- Clareon PanOptix Pro$146
- iStent Trabecular Micro-Bypass System Model iS3$137
- AcrySof IQ PanOptix UV IOL$135
- AcrySof IQ VIVITY$128
- LUMIGAN$120
- ACTHAR$117
- Tecnis IOL$110
How this compares
$7,022 in reported general payments places this provider in the 70th percentile of 64 glaucoma specialist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 226 | $122,046 |
| RhopressaNetarsudil Mesylate | 139 | $67,425 |
| RocklatanNetarsudil Mesylat/Latanoprost | 130 | $59,161 |
| VyzultaLatanoprostene Bunod | 93 | $36,479 |
| Latanoprost | 1,943 | $32,330 |
| Alphagan PBrimonidine Tartrate | 84 | $31,758 |
| CombiganBrimonidine Tartrate/Timolol | 76 | $28,872 |
| Brinzolamide | 109 | $22,117 |
| Travoprost | 100 | $21,737 |
| Brimonidine Tartrate | 308 | $21,034 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 68 | $18,205 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 108 | $17,790 |
| RestasisCyclosporine | 13 | $14,614 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 670 | $13,900 |
| TafluprostTafluprost/Pf | 62 | $13,778 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Combigan, Restasis | $2,015 | $197,290399 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $192 | $36,47993 claims |
| AlconSimbrinza, Azopt | $1,919 | $29,83687 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 glaucoma specialist providers in California.
Other glaucoma specialist in Chula Vista
- Jason BacharachPetaluma$1.7M
- Billy PanBeverly Hills$250K
- Jacob BrubakerSacramento$229K
- Felise May BarteSanta Clara$121K
- Houman VosoghiWestlake Village$119K
- Robert ChangStanford$105K
- Sophia WangStanford$77K
- Jeffrey GoldbergStanford$57K
- Valentina LozanoCulver City$51K
- Sameh MosaedIrvine$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.